Dokumenttyp: journal article
Autor(en) des Beitrags:
Greinix, HT; van Besien, K; Elmaagacli, AH; Hillen, U; Grigg, A; Knobler, R; Parenti, D; Reddy, V; Theunissen, K; Michallet, M; Flowers, ME; UVADEX Chronic GVHD Study Group; Mistrik, M; Durrant, S; van Besien, K; Dodds, T; Elmaagacli, AH; Hillen, U; Reddy, V; Theunissen, K; Machado, AM; Michallet, M; Kolb, HJ; Grigg, A; Bouzas, L; Taylor, P; Flowers, ME; Greinix, HT; Knobler, R
Titel des Beitrags:
Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study.
Abstract:
In a prior multicenter randomized controlled trial, we found that a 12-week course of extracorporeal photopheresis (ECP) plus standard immunosuppressive therapy resulted in several beneficial outcomes in patients with corticosteroid-refractory/intolerant/dependent chronic graft-versus-host disease (GVHD). Here, we report the results of an open-label crossover ECP study in 29 eligible participants randomized initially to the standard of care non-ECP (control) arm. Eligible for the crossover ECP study were control arm patients who either (1) had progression of cutaneous chronic GVHD (cGVHD), defined as >25% worsening from baseline as measured by the percent change in the total skin score (TSS) at any time, or (2) had less than 15% improvement in the TSS, or had a >50% reduction in corticosteroid dose at weeks 12 and 24 was observed. Extracutaneous cGVHD response was highest in oral mucosa with 70% complete and partial resolution after week 24. In conclusion, progressive improvement
in cutaneous and extracutaneous cGVHD was observed after a 24-week course of ECP in patients who previously had no clinical improvement or exhibited worsening of cGVHD while receiving standard immunosuppressive therapy alone in a randomized study. These results confirm previous findings and support the notion that prolonged ECP appears to be necessary for optimal therapeutic effects in corticosteroid-refractory cGVHD patients.